{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:34:22Z","timestamp":1792978462454,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,23]]},"DOI":"10.7759\/cureus.60898","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T09:07:46Z","timestamp":1716455266000},"source":"Crossref","is-referenced-by-count":3,"title":["Safety and Effectiveness of Liv.52 DS in Patients With Varied Hepatic Disorders: An Open-Label, Multi-centre, Phase IV Study"],"prefix":"10.7759","author":[{"given":"Sachin K","family":"Shivnitwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishwar","family":"Gilada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul V","family":"Rajkondawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep K","family":"Ojha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Katiyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navneet","family":"Arya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U. V","family":"Babu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Kumawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-023-01028-x","article-title":"Incidence, prevalence and mortality of chronic liver diseases in Sweden between 2005 and 2019","volume":"38","author":"Nasr P","year":"2023","unstructured":"Nasr P, von Seth E, Mayerhofer R, Ndegwa N, Ludvigsson JF, Hagstr\u00f6m H. Incidence, prevalence and mortality of chronic liver diseases in Sweden between 2005 and 2019. Eur J Epidemiol. 2023, 38:973-84. 10.1007\/s10654-023-01028-x","journal-title":"Eur J Epidemiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update","volume":"79","author":"Devarbhavi H","year":"2023","unstructured":"Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023, 79:516-37. 10.1016\/j.jhep.2023.03.017","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/cld.1177","article-title":"Epidemiology of liver diseases in India","volume":"19","author":"Mondal D","year":"2022","unstructured":"Mondal D, Das K, Chowdhury A. Epidemiology of liver diseases in India. Clin Liver Dis (Hoboken). 2022, 19:114-7. 10.1002\/cld.1177","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.49920","article-title":"Diagnosis and treatment of liver disease: current trends and future directions","volume":"15","author":"Wazir H","year":"2023","unstructured":"Wazir H, Abid M, Essani B, et al.. Diagnosis and treatment of liver disease: current trends and future directions. Cureus. 2023, 15:e49920. 10.7759\/cureus.49920","journal-title":"Cureus"},{"key":"ref5","article-title":"Chronic liver disease","author":"Sharma A","year":"2024","unstructured":"Sharma A, Nagalli S. Chronic liver disease. StatPearls [Internet]. StatPearls Publishing, Treasure Island; 2024 Jan-."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/gastroent14030021","article-title":"Hepatoprotective effects of Liv.52 in chronic liver disease preclinical, clinical, and safety evidence: a review","volume":"14","author":"Kantharia C","year":"2023","unstructured":"Kantharia C, Kumar M, Jain MK, et al.. Hepatoprotective effects of Liv.52 in chronic liver disease preclinical, clinical, and safety evidence: a review. Gastroenterol Insights. 2023, 14:293-308. 10.3390\/gastroent14030021","journal-title":"Gastroenterol Insights"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/gastroent13040037","article-title":"Clinical and safety evaluation of Liv.52 in alcoholic liver disease: a review","author":"Ganesh S","year":"202213","unstructured":"Ganesh S, Joshi N, Jain MK, et al.. Clinical and safety evaluation of Liv.52 in alcoholic liver disease: a review. Gastroenterol Insights. 202213, 377-86. 10.3390\/gastroent13040037","journal-title":"Gastroenterol Insights"},{"key":"ref8","article-title":"Role of Liv.52 DS tablets as a hepatoprotective agent in tuberculosis patients receiving antitubercular drugs: a double blind placebo controlled study","volume":"5","author":"Choijamts G","year":"2018","unstructured":"Choijamts G, Batsyren C, Otgontyr, et al.. Role of Liv.52 DS tablets as a hepatoprotective agent in tuberculosis patients receiving antitubercular drugs: a double blind placebo controlled study . J Liv Clin Res. 2018, 5:1042.","journal-title":"J Liv Clin Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30866","article-title":"Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases","volume":"71","author":"Crabb DW","year":"2020","unstructured":"Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2020, 71:306-33. 10.1002\/hep.30866","journal-title":"Hepatology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2004.10.003","article-title":"The efficacy of Liv-52 on liver cirrhotic patients: a randomized, double-blind, placebo-controlled first approach","volume":"12","author":"Huseini HF","year":"2005","unstructured":"Huseini HF, Alavian SM, Heshmat R, Heydari MR, Abolmaali K. The efficacy of Liv-52 on liver cirrhotic patients: a randomized, double-blind, placebo-controlled first approach. Phytomedicine. 2005, 12:619-24. 10.1016\/j.phymed.2004.10.003","journal-title":"Phytomedicine"},{"key":"ref11","article-title":"Role of Liv.52 in non-infectious chronic liver disease2022","volume":"14","author":"Al-Khazraji KA","year":"2022","unstructured":"Al-Khazraji KA, Khalid AQ, Hashim MK, et al.. Role of Liv.52 in non-infectious chronic liver disease2022. Glob J Health Sci. 2022, 14:","journal-title":"Glob J Health Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/medicina56030097","article-title":"Iranian medicinal plants: from ethnomedicine to actual studies","volume":"56","author":"Buso P","year":"2020","unstructured":"Buso P, Manfredini S, Reza Ahmadi-Ashtiani H, Sciabica S, Buzzi R, Vertuani S, Baldisserotto A. Iranian medicinal plants: from ethnomedicine to actual studies. Medicina (Kaunas). 2020, 56:10.3390\/medicina56030097","journal-title":"Medicina (Kaunas)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(02)00077-3","article-title":"Antiherpes simplex virus type 2 activity of casuarinin from the bark of Terminalia arjuna Linn","volume":"55","author":"Cheng HY","year":"2002","unstructured":"Cheng HY, Lin CC, Lin TC. Antiherpes simplex virus type 2 activity of casuarinin from the bark of Terminalia arjuna Linn. Antiviral Res. 2002, 55:447-55. 10.1016\/S0166-3542(02)00077-3","journal-title":"Antiviral Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcme.2014.12.002","article-title":"Extract of a polyherbal formulation ameliorates experimental nonalcoholic steatohepatitis","volume":"6","author":"Azeemuddin M","year":"2016","unstructured":"Azeemuddin M, Rafiq M, Anturlikar SD, Sharath Kumar LM, Patki PS, Babu UV, Shyam R. Extract of a polyherbal formulation ameliorates experimental nonalcoholic steatohepatitis. J Tradit Complement Med. 2016, 6:160-7. 10.1016\/j.jtcme.2014.12.002","journal-title":"J Tradit Complement Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d3897","article-title":"How big a problem is non-alcoholic fatty liver disease?","volume":"343","author":"Anstee QM","year":"2011","unstructured":"Anstee QM, McPherson S, Day CP. How big a problem is non-alcoholic fatty liver disease?. BMJ. 2011, 343:d3897. 10.1136\/bmj.d3897","journal-title":"BMJ"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.IJEM_585_17","article-title":"Nonalcoholic fatty liver disease and type 2 diabetes mellitus","volume":"22","author":"Dharmalingam M","year":"2018","unstructured":"Dharmalingam M, Yamasandhi PG. Nonalcoholic fatty liver disease and type 2 diabetes mellitus. Indian J Endocrinol Metab. 2018, 22:421-8. 10.4103\/ijem.IJEM_585_17","journal-title":"Indian J Endocrinol Metab"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s43066-023-00299-z","article-title":"Association between the severity of liver cirrhosis with quality of life and its impact on clinical practice","author":"Mustika S","year":"202313","unstructured":"Mustika S, Susanto JP, Lesmana CRA. Association between the severity of liver cirrhosis with quality of life and its impact on clinical practice. Egypt Liver J. 202313, 66. 10.1186\/s43066-023-00299-z","journal-title":"Egypt Liver J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-019-0984-2","article-title":"The association of liver function and quality of life of patients with liver cancer","volume":"19","author":"Li L","year":"2019","unstructured":"Li L, Mo F, Hui EP, et al.. The association of liver function and quality of life of patients with liver cancer. BMC Gastroenterol. 2019, 19:66. 10.1186\/s12876-019-0984-2","journal-title":"BMC Gastroenterol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-804274-8.00044-8","article-title":"Chapter 44 - Herbal drugs on the liver","author":"Girish C","year":"2017","unstructured":"Girish C, Pradhan SC. Chapter 44 - Herbal drugs on the liver. Liver Pathophysiology. Muriel P (ed): Academic Press, Boston; 2017. 605:20. 10.1016\/B978-0-12-804274-8.00044-8"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510310247","article-title":"Herbal products for liver diseases","volume":"31","author":"Mitra SK","year":"2000","unstructured":"Mitra SK. Herbal products for liver diseases. Hepatology. 2000, 31:546-7. 10.1002\/hep.510310247","journal-title":"Hepatology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.18203\/2319-2003.ijbcp20164135","article-title":"A prospective, multicentre, observational study of patients with chronic cholestatic liver diseases receiving Udiliv\u00ae in India: Splendid study","volume":"2621","author":"Lawate PS","year":"20165","unstructured":"Lawate PS, Rooprai R, Choudhury G, et al.. A prospective, multicentre, observational study of patients with chronic cholestatic liver diseases receiving Udiliv\u00ae in India: Splendid study. Int J Basic Clin Pharmacol. 20165, 2621:9. 10.18203\/2319-2003.ijbcp20164135","journal-title":"Int J Basic Clin Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/249160-safety-and-effectiveness-of-liv52-ds-in-patients-with-varied-hepatic-disorders-an-open-label-multi-centre-phase-iv-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T09:07:50Z","timestamp":1716455270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/249160-safety-and-effectiveness-of-liv52-ds-in-patients-with-varied-hepatic-disorders-an-open-label-multi-centre-phase-iv-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.60898","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,23]]}}}